FINWIRES · TerminalLIVE
FINWIRES

AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

By
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition

AbbVie (ABBV) lowered its full-year earnings guidance on Friday to account for the expected dilution from its planned acquisition of Apogee Therapeutics (APGE), despite reporting stronger-than-expected second-quarter results.

The biopharmaceutical company now expects earnings per share of $13.87 to $14.07 for 2026, compared with its prior estimate of $13.91 to $14.11. The updated guidance's midpoint of $13.97 falls short of the FactSet-polled consensus of $14.06.

AbbVie expects the proposed acquisition of Apogee, which was announced last month and is expected to close in the third quarter, to be $0.14 dilutive this year. The all-cash transaction valued at about $10.9 billion will give AbbVie access to Apogee's portfolio of clinical-stage candidates currently in development for the treatment of inflammatory and immunological diseases, including potential atopic dermatitis therapy zumilokibart.

"That is more than offsetting our underlying overperformance," Chief Financial Officer Scott Reents said at an earnings call, according to a FactSet transcript, referring to the anticipated dilution.

AbbVie's stock was down 1.3% intraday, trimming the year-to-date gain to about 11%.

Adjusted EPS for the June quarter rose to $3.65 from $2.97 a year earlier, surpassing the consensus of $3.60. Net revenue grew 10% to $16.99 billion, while analysts expected $16.78 billion.

"AbbVie delivered another excellent quarter, marked by outstanding execution and pipeline advancement," Chief Executive Robert Michael said in the earnings release. "Based on our substantial momentum, AbbVie's long-term outlook remains very strong."

Earlier this month, Johnson & Johnson (JNJ) raised its full-year outlook after reporting better-than-expected second-quarter results, driven by growth in its innovative medicine and medical device businesses. On Thursday, Bristol-Myers Squibb (BMY) also raised its full-year guidance after reporting second-quarter results.

AbbVie's immunology portfolio generated $8.79 billion in global sales during the second quarter, up 15% year over year, with Skyrizi and Rinvoq both delivering more than 20% growth in revenue to offset weak Humira sales.

Global sales from the neuroscience segment jumped 20% to $3.23 billion, while revenue in the aesthetics portfolio increased 0.3% to $1.28 billion. Oncology portfolio sales fell 1.5% to $1.65 billion.

The company expects third-quarter revenue of $17.2 billion, lower than the FactSet-polled consensus of $17.35 billion. Adjusted EPS for the ongoing quarter is expected between $3.84 and $3.88, compared with Wall Street's estimate of $3.87.

Price: $253.60, Change: $-3.82, Percent Change: -1.48%

Related Articles

Wire

Update: BHP Group Faces Strike Action in Western Australia's Pilbara

(Updates to add BHP's statement in the fourth and fifth paragraphs and share movement in the last paragraph)BHP Group (ASX:BHP) is facing another strike from members of three unions in Western Australia's Pilbara region who have decided to impose a 24-hour ship-loading ban on Aug. 8 and will also down tools on Aug. 9, according to multiple media reports on Friday.According to an Australian Financial Review report, the company expects that a work stoppage at Port Hedland will impact AU$120 million in revenue per day.The combined union decision comes after a failed strike over pay disputes that took place on July 16, which was not attended by enough workers to cause a serious disruption.In response to' request for comment, a BHP spokesperson said that the company has plans in place to continue operations despite the potential disruptions.The company has a formal meeting convened by the Fair Work Commission scheduled for next Tuesday to progress bargaining and will seek further assistance from the Commission if needed, the spokesperson added.The company's shares rose almost 2% in recent Friday trade.

ASX:BHP
Wire

Cohu Q2 Adjusted Earnings, Revenue Rise; Shares Jump After Hours

Cohu (COHU) reported Q2 adjusted earnings late Thursday of $0.26 per diluted share, up from $0.02 a year earlier.Analysts polled by FactSet expected $0.14.Revenue for the quarter ended June 27 rose to $149 million from $107.7 million a year ago.Analysts projected $144.2 million.Cohu expects Q3 revenue of $170 million, plus or minus $7 million.Analysts project $146.4 million.Cohu shares jumped 21% in after-hours trading.

$COHU
Wire

Western Union Q2 Adjusted Earnings, Revenue Fall; Cuts 2026 Outlook

Western Union (WU) reported Q2 adjusted earnings Thursday of $0.31 per diluted share, down from $0.42 a year earlier.Analysts polled by FactSet expected $0.42.Revenue for the quarter ended June 30 was $1.01 billion, compared with $1.03 billion a year earlier.Analysts expected $1.02 billion.The company now expects 2026 adjusted EPS of $1.25 to $1.35, down from $1.75 to $1.85. Analysts expect $1.72.Full-year revenue is now expected to grow 3% to 5%, compared with 5% to 8% expected earlier.

$WU